SCHEMBL4869055

SCHEMBL4869055

O=C(Nc1ccccc1O)N1CCCCc2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
MAPT P10636 2/20 0.57
THRB P10828 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 2/20 0.55
NPC1 O15118 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
USP2 O75604 1/20 0.54
POLB P06746 2/20 0.54
TSHR P16473 1/20 0.53
RECQL P46063 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868401 0.85 THRB (0.59) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL14089573 0.85 MEN1 (0.62) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL4869819 0.82 THRB (0.56) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL4867471 0.82 TP53 (0.81) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL4863076 0.81 MAPT (0.69) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL4869023 0.81 TP53 (0.78) MEN1KMT2AMAPTTHRBSMN1; SMN2
SCHEMBL4868252 0.80 MEN1 (0.57) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL4871226 0.80 CHRM2 (0.61) MEN1KMT2AMAPTTHRBUSP2
SCHEMBL4870081 0.80 LMNA (0.53) MEN1KMT2AMAPTTHRBTP53
SCHEMBL4871151 0.80 MAPT (0.67) MEN1KMT2AMAPTTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MEN1 651/4885KMT2A 2577/4885MAPT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.